The effects of pentoxifylline (Trental) on circulating platelet aggregates and platelet aggregation patterns in patients with chronic obstructive arteriosclerotic disease¹

Article type: Research Article

Authors: Ambrus, Julian L. | Anain, Joseph M. | Anain, Shirley M. | Anain, Paul M. | Anain, Joseph M. | Stadler Jr.,, Steven | Fisher, David | Mahafzah, Mahmoud | Hammad, Ali | Savitsky, J. Philip

Affiliations: From the Roswell Park Memorial Institute, the Sister’s of Charity Hospital, the State University of New York at Buffalo, Departments of Internal Medicine, and Surgery, Buffalo, NY and Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ, USA

Note: [1] We are grateful to the Hoechst-Roussel Research Laboratory, Somerville, New Jersey for performing blood pentoxifylline level determinations.

Note: [] Accepted by: Editor A.M. Ehrly

Abstract: Ten patients with intermittent claudication due to chronic obstructive arteriosclerotic disease (COAD) and ten control subjects without vascular disease were studied for the presence of circulating platelet aggregates. Patients exhibited significantly more platelet aggregates in their circulation than did the control subjects. The numbers of platelet aggregates were normalized after 1 1/2 years of therapy with 400 mg pentoxifylline (Trental) three times da1ly in the COAD patients. Higher single doses of pentoxifylline (800 and 1200 mg) given to the COAD patients inhibited ADP-induced platelet aggregation over a period of 6 hours post-dose.

Keywords: Chronic obstructive arteriosclerotic disease, intermittent claudication, pentoxifylline, platelet aggregation

DOI: 10.3233/CH-1990-10208

Journal: Clinical Hemorheology and Microcirculation, vol. 10, no. 2, pp. 225-230, 1990